halcinonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids for topical use, acetal derivatives 4507 3093-35-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • halcinonide
  • alcinonide
  • halciderm
  • halcimat
  • halog
A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.
  • Molecular weight: 454.96
  • Formula: C24H32ClFO5
  • CLOGP: 3.31
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.83
  • ALOGS: -4.61
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1974 FDA RANBAXY

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AD02 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, very potent (group IV)
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:131809 smoothened receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Glaucoma contraindication 23986001 DOID:1686
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Tuberculosis of skin contraindication 66986005
Bilateral cataracts contraindication 95722004
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST Ki 9.14 DRUG MATRIX CHEMBL
Androgen receptor Transcription factor Ki 6.23 DRUG MATRIX
Progesterone receptor Transcription factor Ki 9.92 DRUG MATRIX

External reference:

IDSource
D01308 KEGG_DRUG
4017606 VUID
N0000145986 NUI
4017606 VANDF
CHEBI:31663 CHEBI
CHEMBL1200845 ChEMBL_ID
3392 INN_ID
DB06786 DRUGBANK_ID
SI86V6QNEG UNII
227517 RXNORM
321821 MMSL
4814 MMSL
579 MMSL
002200 NDDF
29058003 SNOMEDCT_US
395735005 SNOMEDCT_US
C0018513 UMLSCUI
D006206 MESH_DESCRIPTOR_UI
443943 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Halcinonide HUMAN PRESCRIPTION DRUG LABEL 1 0378-8056 CREAM 1 mg TOPICAL ANDA 21 sections
Halog HUMAN PRESCRIPTION DRUG LABEL 1 10631-094 CREAM 1 mg TOPICAL NDA 20 sections
HALOG HUMAN PRESCRIPTION DRUG LABEL 1 10631-095 SOLUTION 1 mg TOPICAL NDA 19 sections
HALOG HUMAN PRESCRIPTION DRUG LABEL 1 10631-096 OINTMENT 1 mg TOPICAL NDA 20 sections
HALCINONIDE HUMAN PRESCRIPTION DRUG LABEL 1 57664-698 CREAM 1 mg TOPICAL NDA authorized generic 20 sections
Halcinonide HUMAN PRESCRIPTION DRUG LABEL 1 71428-011 CREAM 1 mg TOPICAL ANDA 20 sections
Halcinonide HUMAN PRESCRIPTION DRUG LABEL 1 71428-011 CREAM 1 mg TOPICAL ANDA 20 sections